Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares saw an uptick in trading volume on Friday . 471,292 shares traded hands during trading, an increase of 114% from the previous session’s volume of 219,724 shares.The stock last traded at $16.88 and had previously closed at $17.67.

Analyst Ratings Changes

Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company.

Enliven Therapeutics Price Performance

The company has a market capitalization of $763.94 million, a P/E ratio of -7.52 and a beta of 1.06. The stock’s fifty day simple moving average is $17.02 and its 200-day simple moving average is $14.33.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. On average, research analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Insider Activity

In other news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the sale, the insider now owns 771,983 shares in the company, valued at $11,579,745. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $19.99, for a total transaction of $25,387.30. Following the sale, the director now directly owns 137,155 shares of the company’s stock, valued at $2,741,728.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the transaction, the insider now directly owns 771,983 shares of the company’s stock, valued at approximately $11,579,745. The disclosure for this sale can be found here. Over the last three months, insiders sold 763,661 shares of company stock valued at $13,213,762. 45.80% of the stock is owned by company insiders.

Institutional Trading of Enliven Therapeutics

Institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its stake in Enliven Therapeutics by 4,476.0% in the second quarter. BlackRock Inc. now owns 1,546,475 shares of the company’s stock valued at $31,564,000 after acquiring an additional 1,512,680 shares during the period. State Street Corp grew its stake in shares of Enliven Therapeutics by 4,847.5% in the 2nd quarter. State Street Corp now owns 466,251 shares of the company’s stock valued at $9,516,000 after purchasing an additional 456,827 shares during the period. Geode Capital Management LLC raised its holdings in shares of Enliven Therapeutics by 1,071.1% in the 2nd quarter. Geode Capital Management LLC now owns 414,444 shares of the company’s stock worth $8,459,000 after buying an additional 379,056 shares in the last quarter. Northern Trust Corp acquired a new position in Enliven Therapeutics during the second quarter worth $3,999,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Enliven Therapeutics by 150.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 156,631 shares of the company’s stock valued at $2,140,000 after purchasing an additional 94,169 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.